论文部分内容阅读
哈药集团有限公司是集科、工、贸于一体的大型骨干企业,是国务院批准的120户大型企业集团试点单位之一。哈药集团有限公司现控股一个上市公司、拥有13个全资子公司、3个关联公司,有职工2.01万人。哈药集团共生产医药原料、西药制剂及中成药、中药粉针、生物工程等6大系列、20多种剂型、1000多个品种的药品,在主导产品中,头孢唑啉钠、头孢噻肟钠、双黄连粉针等产销量均居全国第一位。在销售方面,它有130个销售办事处,遍布30个省市自治区,其产品已打入欧洲、亚洲、非洲、中北美洲市场。
Harbin Pharmaceutical Group Co., Ltd. is a large-scale backbone enterprise integrating science, industry and trade, and is one of the pilot units of 120 large-scale enterprise groups approved by the State Council. Harbin Pharmaceutical Group Co., Ltd. currently controls a listed company, owns 13 wholly-owned subsidiaries, 3 affiliates, and employs 20,100 employees. Harbin Pharmaceutical Group produces a total of 6 series, 20 kinds of dosage forms and more than 1,000 varieties of pharmaceutical raw materials, western medicine preparations and Chinese patent medicines, traditional Chinese medicine injections, and bioengineering products. Among the leading products, cefazolin sodium and cefotaxime are the main products. Sodium, Shuanghuanglian injection and other production and sales ranks first in the country. In terms of sales, it has 130 sales offices in 30 provinces, municipalities and autonomous regions, and its products have entered the European, Asian, African, Central and North American markets.